Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 127 entries
View as:

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Phase: N/A Priority: Normal
NCT ID: NCT01835236 Org: User:
Start: 03/03/13 End: 05/26/20 Due: 05/26/21

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Phase: N/A Priority: Normal
NCT ID: NCT04604067 Org: User:
Start: 06/25/21 End: 12/31/30 Due: 12/31/31

Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01926964 Org: User:
Start: 09/30/13 End: 02/28/15 Due: 02/28/16

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00217698 Org: User:
Start: 11/30/03 End: 10/31/04 Due: 10/31/05

Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00003230 Org: User:
Start: 01/31/98 End: 07/31/00 Due: 07/31/01

Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC

Phase: N/A Priority: Normal
NCT ID: NCT02058056 Org: User:
Start: 07/11/14 End: 12/03/18 Due: 12/03/19

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02404506 Org: User:
Start: 08/17/15 End: 07/22/21 Due: 07/22/22

Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00238407 Org: User:
Start: 03/31/04 End: 08/31/10 Due: 08/31/11

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Phase: N/A Priority: Normal
NCT ID: NCT03886649 Org: User:
Start: 11/04/19 End: 03/08/22 Due: 03/08/23

Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00544700 Org: User:
Start: 11/26/07 End: 12/12/19 Due: 12/12/20

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Phase: N/A Priority: Normal
NCT ID: NCT06358573 Org: User:
Start: 10/24/24 End: 12/31/29 Due: 12/31/30

Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00031876 Org: User:
Start: 05/31/00 End: 09/30/04 Due: 09/30/05

Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT00334594 Org: User:
Start: 11/14/05 End: 01/23/18 Due: 01/23/19

Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Phase: N/A Priority: Normal
NCT ID: NCT00003902 Org: User:
Start: 03/31/99 End: 09/30/05 Due: 09/30/06

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Phase: N/A Priority: Normal
NCT ID: NCT02964689 Org: User:
Start: 04/12/17 End: 07/02/21 Due: 07/02/22

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Phase: N/A Priority: Normal
NCT ID: NCT02640534 Org: User:
Start: 06/10/16 End: 03/16/23 Due: 03/16/24

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Phase: N/A Priority: Normal
NCT ID: NCT02053311 Org: User:
Start: 08/19/14 End: 08/19/34 Due: 08/19/35

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01307605 Org: User:
Start: 02/09/11 End: 01/25/23 Due: 01/25/24

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Phase: N/A Priority: Normal
NCT ID: NCT03708003 Org: User:
Start: 03/11/19 End: 12/31/26 Due: 12/31/27

Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00030732 Org: User:
Start: 06/30/01 End: 04/30/08 Due: 04/30/09

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03387917 Org: User:
Start: 11/12/18 End: 12/22/23 Due: 12/22/24

Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00217711 Org: User:
Start: 05/31/05 End: 10/31/11 Due: 10/31/12

Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00445406 Org: User:
Start: 12/31/06 End: 03/31/09 Due: 03/31/10

External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00869570 Org: User:
Start: 03/31/09 End: 09/30/16 Due: 09/30/17

Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00003757 Org: User:
Start: 02/28/98 End: 07/31/07 Due: 07/31/08